BioSpace News Archive

Aro Biotherapeutics announced the enrollment of the first subject in its Phase 1 trial of ABX1100, Aro’s lead Centyrin-siRNA program for the treatment of Pompe Disease.

LivaNova PLC announced Bill Kozy, Interim Chief Executive Officer and Board Chair of LivaNova, will present a general business update during fireside chats at two healthcare conferences in New York in November.

Plus Therapeutics, Inc. announced that it will present four posters and one oral presentation at the Society for NeuroOncology 28th Annual Meeting being held November 15-19, 2023 in Vancouver, Canada.

Regen BioPharma, Inc. has previously discussed initiation of a series of experiments to validate its DuraCAR CAR T-cell therapeutic.

On October 22, Qilu Pharmaceutical unveiled the latest findings from a multicenter, single-arm Phase II clinical trial at the European Society for Medical Oncology (ESMO) Annual Congress 2023.

Focal Medical, Inc., a privately held, biopharmaceutical company developing novel precision therapeutic products today announced successful completion of the nonclinical development phase of Focal Medical’s Implantable Iontophoresis Chemotherapy Delivery Device with Gemcitabine (ACT-IOP-003).

Visceral fat, also known as Visceral Adipose Tissue (VAT), is the adipose tissue inside the abdominal cavity. VAT is a central risk factor for Non-Alcoholic Fatty Liver Disease (NAFLD), liver cirrhosis, cardiovascular disease (CVD), and type-2 diabetes (T2D).

Biogen Inc. (Nasdaq: BIIB) reported new Phase 1b clinical data from the study of BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, in mild Alzheimer’s disease (AD).

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) today announced additional positive interim results for the ongoing single ascending dose portion of the Phase 1 study of ALN-APP, an investigational RNAi therapeutic targeting amyloid precursor protein (APP) in development for the treatment of Alzheimer’s disease and cerebral amyloid angiopathy (CAA).

Elixir Medical, a developer of novel cardiovascular technologies, today announced positive six-month clinical data from the DESyne BDS Plus Randomized Controlled Trial (RCT) evaluating DESyne BDS Plus, the world’s first triple drug-eluting coronary implant with site-specific delivery of antithrombotic drugs versus a second-generation, durable polymer drug-eluting stent (DES).